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The hepatitis B virus X gene product trans activates transcription from a variety of viral and cellular
regulatory elements. We expressed the complete, nonfused X protein in Escherichia coli and showed it to be
active in trans activating a human immunodeficiency virus long terminal repeat-linked chloramphenicol
acetyltransferase reporter gene.
Hepatitis B virus (HBV) contains an open reading frame
called X, located between nucleotide positions 1376 and 1840
(in subtype adw), and encodes a protein of 154 amino acids
or 16,560 daltons (9). The precise role of X protein during
HBV infection is not clear. However, recent studies have
established a trans-activating function for this protein (6-8,
13). With various cell lines, cotransfection studies using
reporter gene systems have shown that the X gene product
can activate transcription from the following regulatory
elements: the HBV enhancer (1, 7), the simian virus 40
enhancer (8, 13), the human immunodeficiency virus (HIV)
long terminal repeat (LTR) (6, 7, 10), the Rous sarcoma virus
LTR (7, 13), the human T-lymphotropic virus type LTR (13),
the herpes simplex virus thymidine kinase promoter (13),
and the beta interferon gene promoter (11). This trans-
activating property has also been established in human liver
cells that stably express the X gene (7), as well as by
integrated X gene sequences isolated from hepatocellular
carcinoma tissue (12). Deletion mutagenesis studies on the
HIV LTR (7, 10) have mapped the X-responsive elements
within the enhancer region containing two direct repeats of
the sequence GGGACTTTCC. These sequences are target
sites for a transcription factor, NF-KB (5). Sequences bear-
ing close homology to the NF-KB binding site are also
present in at least some of the other X-responsive regulatory
elements.
Little is known about the mechanisms of X-mediated
regulation. Our interest is detailed structure-function analy-
sis of the X protein to elucidate domains important for its
activity. Two important prerequisites for this are the avail-
ability of large amounts of the active protein and an assay
system to assess its functional activity. Therefore, we ex-
pressed the HBV X protein in Escherichia coli and purified
it to homogeneity. Further, by using a simple cellular uptake
assay, we demonstrated that the protein synthesized in E.
coli displays a trans-activating function in cultured mamma-
lian cells.
An expression system based on T7 RNA polymerase
(F. W. Studier, A. H. Rosenberg, and J. J. Dunn, Methods
Enzymol., in press) was used in this study. An NcoI-BglII
fragment of HBV (nucleotides 1375 to 1987) was cloned
between the NcoI and BamHI sites of the vector pET-8C
(Studier et al., in press) to yield plasmid pET-X (Fig. 1A).
This placed the entire X open reading frame, including
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methionine codon 1, directly downstream of the T7 promoter
and the ribosome-binding site in the vector. Expression was
done in BL21 (DE3), which is a protease-deficient (Lon-
ompT-) strain of E. coli containing a bacteriophage lambda
lysogen that, on induction with isopropyl-p-D-thiogalactopy-
ranoside (IPTG), expresses the T7 RNA polymerase gene. A
16- to 17-kilodalton protein was inducibly expressed in cells
containing plasmid pET-X but not in cells with control
plasmid pET-8C (Fig. 1B).
To establish that the 16- to 17-kilodalton protein is in fact
the HBV X protein, a Western immunoblotting experiment
was performed. Polyclonal antisera against two synthetic
peptides from the HBV X protein were raised in rabbits.
These peptides included amino acids 100 to 114 (HBX100) or
144 to 154 (HBX144) and were coupled to keyhole limpet
hemocyanin or purified protein derivative, respectively,
before injection. Proteins synthesized in transformed E. coli
induced with IPTG were separated by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis and transferred to
nitrocellulose. On probing with anti-HBX144, the 16- to
17-kilodalton band was seen only in pET-X transformed cells
(Fig. 2A). Furthermore, a linear response to IPTG induction
was also seen. Similar results were also obtained with
anti-HBX100 (data not shown). To further establish the
specificity of the anti-peptide sera, a cross-competition
Western analysis was done. Nitrocellulose strips containing
total E. coli lysates were incubated with either antiserum
without or with the specific or the nonspecific peptide. The
results (Fig. 2B) showed that a major protein band corre-
sponding to the X protein monomer was eliminated by the
specific peptide (lanes 3 and 7) but not by the nonspecific
peptide (lanes 4 and 6). This showed that the expressed
protein was indeed the HBV X protein. Two extra bands
seen with anti-HBX100 may have been due to bacterial
proteins with homology to the HBX100 peptide sequence.
To purify the expressed X protein, cells from cultures
induced for 3 h were suspended in 5 to 10% of the culture
volume of 50 mM Tris (pH 8.5-10 mM EDTA. After one
freeze-thaw cycle, the cells were disrupted by sonication and
the lysate was centrifuged at 14,000 x g for 15 min. The
pellet was suspended in the above-described buffer contain-
ing 30% (wt/vol) sucrose and collected by centrifugation.
This pellet was dissolved in the above described buffer
containing 6 M urea and 5 mM 2-mercaptoethanol. At this
stage, the mixture was dialyzed against phosphate-buffered
saline (pH 7.2) containing 1 mM 2-mercaptoethanol and used
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FIG. 1. (A) Schematic illustration of expression vector pET-X. (B) Sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis of
proteins present in E. coli transformed with plasmid pET-8C (control) or pET-X (two independent clones, ET-X1 and ET-X2). Cells were
grown at 37°C to an A6. of 0.7 to 1.0 and induced with (+) or without (-) 0.4 mM IPTG for 3 h. Total bacterial proteins were analyzed on
a 15% polyacrylamide gel after staining with Coomassie blue. The arrow indicates the presence of a new 16- to 17-kilodalton protein in
pET-X-transformed cells on IPTG induction is indicated. ORF, Open reading frame; nt, nucleotide; Term., terminator; MW, molecular
weight.
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in functional assays. Alternatively, further purification was
performed by preparative isoelectric focusing. The urea-
solubilized protein mixture was diluted to 48 ml such that the
final buffer strength was 10 mM Tris (pH 8.5)-2 mM EDTA-
1 mM 2-mercaptoethanol. After adding 2 ml of pH 3 to 10
ampholines (Bio-Rad Laboratories), the mixture was elec-
MW X 13 trofocused in a Bio-Rad Rotofor preparative isoelectricfocusing cell for 5 h at 4°C. The X protein peak fractions
focused in the pH range of 7.9 to 8.6 (fractions 12 to 14); the
peak fraction (no. 13) had a pH of 8.3, which is close to the
theoretical pl of 8.5. This gave electrophoretically pure X
protein (Fig. 3).
The only known function of X protein is to trans activate
.27 certain cis-acting regulatory elements. Of these, the HIV
LTR is the best characterized. We used a HeLa cell-derived
line (LTR3CAT) stably transfected with a plasmid contain-
17 ing the bacterial gene for chloramphenicol acetyltransferase
(CAT) under control of the HIV LTR sequences. The assay
systems used were those described earlier-direct cellular
uptake of proteins (4) or scrape loading of cells with proteins
(2). Figure 4 shows the results of expression of the gene for
CAT in the LTR3CAT cell line. Whereas very low back-
ground CAT activity was seen in the cells (lanes 1 and 2),
FIG. 2. Western analysis of X protein expression. (A) Control
and pET-X-transformed E. coli cells were induced, and proteins
were separated by sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis as described in the legend to Fig. 1B. The filter with
transferred protein was blocked with 1% nonfat milk in phosphate-
buffered saline for 2 h followed by successive incubations with a
1:100 dilution of anti-HBX144 (in phosphate-buffered saline-milk)
and a 1:500 dilution of horseradish peroxidase-conjugated goat
anti-rabbit immunoglobulin G (in phosphate-buffered saline) for 2 to
3 h each. The blot was then developed by using 4-chloronaphthol as
the substrate. MW, Molecular weight. (B) Nitrocellulose strips
containing total proteins from pET-X-transformed E. coli were
incubated with preimmune sera (1:100), anti-HBX100 (1:100), or
anti-HBX144 (1:250). For competitions, peptide HBX100 or
HBX144 was also included in the primary antibody incubation at a
concentration of 0.5 mg/ml. The secondary antibody and color
development were as described above. Bands eliminated by specific
peptides (*) and the position of the X protein monomer (arrow) are
indicated.
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FIG. 3. Purification of HBV X protein. A representative prog-
ress of purification is shown. Lanes: 1, total cell lysate; 2, postson-
ication supernatant; 3, 30% sucrose wash of postsonication pellet; 4,
pellet from sucrose wash in 6 M urea; 5, pooled fractions 12 to 14
from isoelectric focusing. MW, Molecular weight.
there was an approximately eightfold increase on scrape
loading of the X protein into these cells (lanes 3 and 4). The
increase was even more pronounced, up to 30-fold, when the
cells were simply overlaid with protein (lanes 5 and 6). This
level of stimulation by X is consistent with the results
obtained by others following DNA transfection (7). This
trans activation appeared to be specific, as there was no
increase in the levels of actin RNA when X protein-con-
taining extract was loaded into LTR3CAT cells compared
with control extracts (data not shown). Thus, the X protein
produced in E. coli was biologically active. The HIV LTR
also seems to be stimulated by the HBV X protein in the
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FIG. 4. Functional activity of X protein. Partially purified pro-
tein extracts were prepared from E. coli transformed with plasmid
pET-X (X extract) or pET-8C (control extract); the protein content
of the former was equivalent to that shown in Fig. 1 and 2. This
preparation, at a total protein concentration of 100 jig/ml, was added
to 2 ml of Dulbecco modified Eagle medium containing 10% fetal
bovine serum and overlaid on a monolayer of LTR3CAT cells. For
scrape loading, the cells were gently scraped off the plate in the
above-described medium and then allowed to settle down. After 6 h
at 37°C, 8 ml of fresh Dulbecco modified Eagle medium with 10%
fetal bovine serum was added and the cells were harvested for CAT
assay (3) after another 24 h. Lanes 1, 3, and 4 contained cells scrape
loaded with Dulbecco modified Eagle medium, X, and control
extracts, respectively. Lanes 2, 5, and 6 contained cells overlaid
with Dulbecco modified Eagle medium, X, and control extracts,
respectively. Fold stimulation of CAT activity over the background
is indicated. Cm, [14C]chloramphenicol; a, 1-acetate; b, 3-acetate.
environment of lymphocytic and hepatic cell types (H.
Maguire, unpublished data). Although cell-specific differ-
ences are expected, it appears that X can function as a
standard trans activator in a variety of cell types.
Several possible mechanisms can be invoked to explain
the trans-activating function of the HBV X protein. The
protein may directly bind to target DNA sequences within a
given response element, for example NF-KB-like se-
quences. This, however, is unlikely because of the rather
ubiquitous nature of X-mediated trans activation. Not all of
its target genes contain NF-KB-like sequences or other
defined sequence homologies in their regulatory regions. We
tried direct DNA-binding experiments with E. coli-
expressed or in vitro-translated X protein and probes con-
taining the HIV LTR, the HBV enhancer, or other subge-
nomic regions of HBV. However, no specific binding ofX to
a DNA fragment was observed (data not shown).
trans-Activator proteins that do not bind DNA directly
may function by entering into complexes with other tran-
scription factors. Protein-protein interactions are fundamen-
tal to regulation of transcription in eucaryotic cells. Without
a DNA-binding function, it is likely that X protein activates
transcription by interacting with or modifying other tran-
scription factors. For example, for the HIV LTR, the
NF-KB factor may be one such transcription factor influ-
enced by X. It is known that under noninducing conditions
or in nonlymphocytic cells, NF-KB is found in the cyto-
plasm, bound to an inhibitor (IKB) (5). HBV X protein may
act, for example, by shifting the equilibrium in favor of free
NF-KB. Availability of pure preparations of X protein will
facilitate inquiry into its ability to interact with other pro-
teins. More detailed analysis remains to be performed in
terms of the domains of X protein essential for trans activa-
tion. Establishment of the good expression and assay sys-
tems reported here forms the basis for future studies.
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